Literature DB >> 2598172

Initial immunochemical characterization of specific macrophage-arming factor.

R A De Weger1, R J Vandebriel, H Slager, D Mans, H Van Loveren, B Wilbrink, H F Dullens, W Den Otter.   

Abstract

This paper describes the initial immunochemical characterization of specific macrophage-arming factor (SMAF). SMAF is an antigen-specific factor that is released by (sensitized) T lymphocytes after contact with the specific antigen. It renders macrophages specifically cytotoxic. The specificity is dependent on the tumor-mouse combination. In allogeneic systems the specificity is H-2-directed, whereas in the syngeneic systems the specificity is tumor-specific. SMAF has a molecular mass of 65-85 kDa (established by gel filtration). By affinity chromatography SMAF could not be adsorbed with anti-(kappa + lambda light chain) immunoglobulins or anti-IgG from SMAF-containing supernatants. SMAF could be adsorbed with the monoclonal antibody 14-30 (directed against specific T-cell factors), and could be eluted from columns containing the latter. Furthermore, SMAF could also be adsorbed with and eluted from affinity chromatography columns to which specific tumor cell membranes or KCl extracts of these tumor cell membranes were coupled. Other tumor cell membranes could not adsorb SMAF. Together these data show that SMAF is not an antibody but a T-cell factor with an antigen-specific recognition site.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2598172     DOI: 10.1007/bf01665026

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  25 in total

1.  Delayed-type hypersensitivity: activation of mast cells by antigen-specific T-cell factors initiates the cascade of cellular interactions.

Authors:  P W Askenase; H Van Loverent
Journal:  Immunol Today       Date:  1983-09

2.  Impairment of allograft tumor immunity by isotype-like suppression of antigen-specific T cell factors.

Authors:  H Van Loveren; R A De Weger; J Garssen; G Los; P W Askenase
Journal:  Transplantation       Date:  1989-03       Impact factor: 4.939

3.  Cytotoxicity of murine peritoneal macrophages in tumour allograft immunity.

Authors:  W Den Otter; R Evans; P Alexander
Journal:  Transplantation       Date:  1972-08       Impact factor: 4.939

4.  Cytotoxicity by macrophages and monocytes.

Authors:  R A De Weger; B A Runhaar; W Den Otter
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

5.  Lymphocyte-induced macrophage cytotoxicity. Production of specific macrophage arming factor by sensitized Lyt 1+2+ T-lymphocytes.

Authors:  E Pels; R A De Weger; W Den Otter
Journal:  Int Arch Allergy Appl Immunol       Date:  1984

6.  Production of specific macrophage-arming factor precedes cytotoxic T lymphocyte activity in vivo during tumor rejection.

Authors:  H F Dullens; R A De Weger; M Van der Maas; P J Den Besten; R J Vandebriel; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  An early component of delayed-type hypersensitivity mediated by T cells and mast cells.

Authors:  H van Loveren; R Meade; P W Askenase
Journal:  J Exp Med       Date:  1983-05-01       Impact factor: 14.307

8.  A role for mast cells and the vasoactive amine serotonin in T cell-dependent immunity to tumors.

Authors:  H Van Loveren; W Den Otter; R Meade; P M Terheggen; P W Askenase
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

9.  Lymphocyte-induced macrophage cytotoxicity. III. Induction of specific macrophage cytotoxicity is independent of lipopolysaccharide.

Authors:  R A de Weger; H van Loveren; J W de Groot; R Rangarajan; W den Otter
Journal:  Immunobiology       Date:  1986-04       Impact factor: 3.144

10.  The induction of lymphocytes with the capacity to render macrophages cytotoxic in an allogeneic murine system.

Authors:  R A De Weger; E Pels; W Den Otter
Journal:  Immunology       Date:  1982-11       Impact factor: 7.397

View more
  1 in total

1.  Production of specific macrophage-arming factor precedes cytotoxic T lymphocyte activity in vivo during tumor rejection.

Authors:  H F Dullens; R A De Weger; M Van der Maas; P J Den Besten; R J Vandebriel; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.